Bempedoic acid inhibits ATP-citrate lyase upstream of HMG-CoA reductase, lowering LDL ~18% without myopathy risk. The CLEAR Outcomes trial (2023) confirmed significant reduction in major cardiovascular events in statin-intolerant patients.
Research summaries are AI-generated from open-access peer-reviewed literature (PubMed Central, Cochrane, AHA/ACC). Content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.